See editorial on page 1207. I ncrease in circulating bilirubin levels reflects hepatic dysfunction and correlates with severity of alcoholic hepatitis. 1, 2 In patients with severe alcoholic hepatitis (SAH), circulating levels of unconjugated bilirubin are high because of impaired hepatic conjugation of bilirubin. 2 In addition, hepatic insufficiency results in hypoalbuminemia, 3 which indirectly increases the circulating levels of free bilirubin, because 90% of unconjugated bilirubin circulates in complex with albumin. 4 This increases the circulatory molar ratio of bilirubin: albumin in patients with SAH. The molar ratio of bilirubin: albumin determines the binding of bilirubin to albumin, 5 which reduces the unbound bilirubin concentration and its toxicity. 4, 6, 7 Chemically, bilirubin is a tetrapyrrole compound 8 and is optically inactive because it racemizes into an isotropic solution. 8, 9 However, when bilirubin binds with albumin (the most available chiral matrices in circulation 10 ), an optically active albumin-bilirubin complex is formed. 5 The optical activity of such compound is measured by circular dichroism (CD) spectroscopy. 11 CD measures the difference in light absorbance between left circularly polarized light and right circularly polarized light when polarized light passes through an optically active substance. 9 ,12 CD spectra of in vitro prepared albumin-bilirubin complex is bisignate in nature (ie, 2 bands of opposite signs) at a wavelength of 300-550 nm. 5, 10, 13 Albumin contains 3 bilirubin binding sites, 1 primary high-affinity site (subdomain IIA), and 2 secondary lowaffinity sites (subdomains IB, IIIA).
14 Using CD spectra of albumin-bilirubin complex, it has been shown that under physiological conditions 1 mole of bilirubin (dianionic state) binds with 1 mole of albumin at the primary site. 4, 11, 13 However, at 3:1 molar ratio of bilirubin: albumin, all 3 binding sites on albumin get engaged by bilirubins. 5, 10 In vitro analysis shows that alteration of albumin or bilirubin levels modulates the formation of albumin-bilirubin complex and its CD spectra. 5 Recently, our group demonstrated structural modifications in albumin in patients with SAH. 15 Structurally modified albumin may have altered bilirubin binding capacity that could also correlate with the progressive nature of the disease and poor outcome. In addition, studies demonstrating the optical activity of circulatory albumin-bilirubin complex (in vivo) under physiological and pathologic conditions are lacking. Simple, fast, and highly reproducible CD spectroscopy could provide a platform for the measurement of optical activity of in vivo (circulatory) albumin-bilirubin complex.
On the basis of these premises, we investigated the optical activity (molecular ellipticity [ME]) of circulatory albumin-bilirubin complexes and correlated it with the severity and outcome in patients with SAH who often have very high bilirubin levels and high mortality. We also studied the association of ME with functionality of circulating albumin because overloading of albumin with bilirubin could reduce its binding capacity.
Methods

Patients
In this cross-sectional study a total of 265 patients with SAH admitted in the Department of Hepatology, Institute of Liver and Biliary Sciences from January 2014 to January 2016 were enrolled. SAH was characterized on the basis of histologic evidence. Whenever liver biopsy was not available, the presence of acute alcoholic hepatitis was confirmed via clinical and laboratory criteria of previously published SAH guidelines. 2, [16] [17] [18] [19] [20] Patients with a history of portal vein thrombosis, recent variceal bleeding (<42 days before enrollment), hepatitis B virus, hepatitis C virus, human immunodeficiency virus infection, hepatocellular carcinoma, or liver transplantation within 90 days of enrollment were excluded from the study. Stable compensated alcoholic cirrhosis (AC) patients (n ¼ 60) abstinent for past 4 weeks were included as disease controls. Thirty healthy controls (HCs) (controls) with no history or clinical evidence of previous or present illness were also studied. Cirrhosis of liver was diagnosed by a combination of clinical, biochemical, histopathologic, endoscopic, and radiologic criteria. 21 Blood samples were drawn from all the enrolled patients at admission. The laboratory staff was unaware of the clinical details of the study groups. The severity of liver disease at the initial presentation was assessed by calculating Model for End-Stage Liver Disease (MELD), Model for End-Stage Liver Disease-Sodium (MELD-Na), Maddrey's discriminant function (DF), and Age, Bilirubin, INR Creatinine (ABIC). In addition, the presence of systemic inflammatory response syndrome (SIRS) and its association with or without sepsis were also assessed in these patients. All patients with SAH were clinically followed up for 12 months or until death, whichever occurred first. The patients were managed according to the standard patient care, management, and therapeutics procedure that include intensive care monitoring, highcalorie nutrition equivalent to 35-40 cal/kg with 1.2-1.5 g protein/kg/day, and terlipressin as required. All patients with SAH received corticosteroids (prednisolone 40 mg/day 19, 22 ) after the collection of blood samples.
Among the total 265 enrolled patients with SAH, the first 100 patients were planned to be considered as the discovery cohort and the subsequent 165 patients as the validation cohort. Ten out of first 100 patients had documented history of albumin dialysis and/or intravenous albumin infusion and were excluded from the study. Furthermore, 15 patients of the latter 165 also had history of albumin dialysis and/or intravenous albumin infusion and were not considered in the study (Supplementary Figure 1) . The study protocol was approved by the ethics committee of the Institute of Liver and Biliary Sciences, and informed consent was obtained from every participant.
Circular Dichroism Spectroscopy-based Measurement of Optical Activity of Circulatory Albumin-Bilirubin Complex
The optical activity of the circulatory albumin-bilirubin complex was measured by CD spectroscopy (Supplementary Methods).
Estimation of Albumin-Binding Capacity
Albumin-binding capacity (ABiC) test was performed to estimate the degree of binding site impairment of circulatory albumin by using an indirect dye binding method (Supplementary Methods).
In Vitro Preparation of Albumin-Bilirubin Complex
To study the interaction between albumin and bilirubin, albumin-bilirubin complexes at various bilirubin: albumin molar ratios were prepared in vitro (Supplementary Methods).
Statistical Analysis
Results are shown as mean AE standard deviation unless indicated otherwise. By using Graph Pad Prism v6 (La Jolla, CA) and IBM SPSS statistics 20.0 (Armonk, NY) statistical analyses were performed, and statistical significance was seen at 5% (P .05). The comparison between 3 groups was performed by using analysis of variance, Kruskal-Wallis test followed by post hoc comparison by Bonferroni method. The comparison between 2 groups was performed by using unpaired (two-tail) Student t test, Mann-Whitney U test. Spearman rho correlation was drawn between prognostic variables. Receiver operating characteristic (ROC) analyses were performed to examine the diagnostic accuracy of the prognostic variables. ROC curves were also inferred to identify cutoff value for ME to predict mortality in patients with SAH. Kaplan-Meier (KM) survival analyses were performed with the selected cutoff values, and probability estimation analysis was performed by using 'R' based analysis. Finally, univariate and multivariate Cox regression analyses were performed to assess the individual value of prognostic variables. C-statistics was performed to compare the ME and MELD score directly. Spearman rho correlation was also drawn between ME and ABiC. .58
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Circulatory Bilirubin: Albumin Molar Ratio in Discovery Cohort
Bilirubin was higher in patients with SAH (0.35 mmol/L) than AC (0.05 mmol/L) and control (0.01 mmol/L; P < .01, Figure 1A ). Serum albumin was lower in patients with SAH (0.35 mmol/L) than AC (0.58 mmol/L) and control (0.77 mmol/L; P < .01, Figure 1B) . The molar ratio of bilirubin: albumin was higher in the first group (1.0) than second (0.09) and third (0.01; P < .01, Figure 1C ), indicating the probability of increased albumin and bilirubin interactions.
Optical Activity (Molecular Ellipticity) of Circulatory Albumin-Bilirubin Complex in Discovery Cohort
Bilirubin: albumin molar ratio was increased in patients with SAH, on which we speculated an increase in concentration of optically active albumin-bilirubin complex in circulation. We observed clear difference in the shapes of CD and ultraviolet (UV)-visible absorption spectra of albumin-bilirubin complex in the patients with SAH as compared with AC and control ( Figure 1D ). ME of albumin-bilirubin complex was higher in patients with SAH (2.46 mdeg) compared with AC (1.10 mdeg) and controls (0.67 mdeg; P < .01, Figure 1E ), indicating increased formation of albumin-bilirubin complexes in circulation in patients with SAH.
Circular Dichroism/Ultraviolet Spectra of In Vitro Albumin-Bilirubin Complex
Patients with SAH showed mean bilirubin: albumin molar ratio of 1.0 with an upper limit of 2.0, whereas mean bilirubin: albumin molar ratio was 0.1 in AC patients and 0.01in HCs. CD/UV spectra of in vitro prepared albumin-bilirubin complex at SAH molar ratio were identical to the CD/UV spectra for SAH plasma (in vivo) ( Figure 1F ). These results suggest that the CD spectra and UV absorbance spectra in the plasma samples correspond to the albumin-bilirubin complexes. In addition, bilirubin at 0.01 mmol/L or 0.35 mmol/L concentration did not show any optical activity but demonstrated specific UV absorbance (Supplementary Figure 2) , reconfirming the fact that free bilirubin is optically inactive.
Correlation of Molecular Ellipticity With Severity and Outcome in Patients With Severe Alcoholic Hepatitis in Discovery Cohort
In the discovery cohort, a total of 66.7% patients with SAH died within 3 months of enrollment in the study. Plasma bilirubin, albumin, and their molar ratio showed no significant difference between survivors and nonsurvivors (Figure 2A-C) . However, the ME was significantly higher in non-survivors (2.92 mdeg) than in survivors (1.47 mdeg, P < .01; Figure 2D ). ME directly correlated with MELD, MELD-Na, and DF (r 2 > 0.3, P < .01; Figure 2E ). Furthermore, ME documented higher diagnostic accuracy with area under the receiver operating characteristic (AUROC) (0.87, 0.79-0.95) as compared with MELD and DF for prediction of 3-month mortality ( Figure 2F ). AUROC for ME was significantly better from AUROC for MELD (P ¼ .04) and DF (P < .01) (Hanley and McNeil method 23 ; Figure 2F ). On further analysis, the AUROC of ME showed cutoff value of 1.84 mdeg with 86% sensitivity, 87% specificity, and optimal Youden index of 0.73 for discrimination between survivors and non-survivors at 3 months. This cutoff was also validated by using Cutoff Finder (http://molpath.charite. de/cutoff 24 ) (Supplementary Figure 3) . Finally, cutoff of 1.84 mdeg was used for KM survival analysis that elucidated higher 3-month mortality in patients with SAH having ME value >1.84 mdeg (log rank < 0.01; Supplementary Figure 4) . The results suggest that ME could be used as a putative indicator of outcome in patients with SAH after proper validation.
Validation of Molecular Ellipticity as Predictor of 3-Month Mortality of Patients With Severe Alcoholic Hepatitis
The potentiality of ME as predictor of mortality in patients with SAH was validated in 150 patients with SAH. ME at a cutoff of 1.84 mdeg was used to divide the validation cohort into 2 groups, SAH with ME <1.84 mdeg (n ¼ 78) and !1.84 mdeg (n ¼ 72) ( Table 2 ). Mortality (3 months) in SAH with ME !1.84 mdeg was significantly higher (73.6%) as compared with 8.9% in SAH with ME <1.84 mdeg (P < .01, Table 2 ). Furthermore, SAH with ME !1.84 mdeg showed significantly higher plasma bilirubin, bilirubin: albumin molar ratio, alanine aminotransferase, total leukocyte counts (TLC), MELD, MELD-Na, and DF scores as compared with SAH with ME <1.84 mdeg (P < .05, Table 2 ). KM curve analysis documented an increase in 3-month mortality in patients with SAH having !1.84 mdeg ME (log rank < 0.01; Figure 3A ). In addition, patients with SAH with !1.84 mdeg ME showed >75% prediction class probability in both discovery cohort ( Figure 3B ) and validation cohort ( Figure 3C ). These results indicate that ME significantly differentiates nonsurvivors from survivors of SAH.
Molecular Ellipticity Is a Predictor of Mortality in Patients With Severe Alcoholic Hepatitis
The ability of ME as a predictor of mortality in patients with SAH was analyzed in the total enrolled patients with SAH (n ¼ 240; discovery cohort 90 and validation cohort 150). SAH with !1.84 mdeg ME documented a relative risk ratio of 4.6 (3.1-6.7) and an odds ratio of 22 (11.4-43. 3) (P < .01) for mortality at 3 months. Cox regression analysis showed ME (hazard ratio [HR], 1.44; 1.31-1.58) and MELD (HR, 1.20; 1.11-1.29) as predictors of 3-month mortality in patients with SAH (n ¼ 240; Table 3 ). Concordance index of ME (0.78, 0.73-0.84) was significantly higher (P ¼ .02) than MELD (0.68, 0.62-0.73) for prediction of 3-month mortality in patients with SAH (n ¼ 240; Table 3 ). In addition, Cox regression analysis of ME with other laboratory parameters also showed ME (HR, 1.53; 1.41-1.66) and SIRS (HR, 1.02; 1.01-1.05) as predictors of 3-month mortality in patients with SAH (n ¼ 240; Supplementary Table 1) .
Correlation of Molecular Ellipticity With Albumin-Binding Capacity in Patients With Severe Alcoholic Hepatitis
Overloading of circulatory albumin with excess bilirubin molecules may interfere with the binding ability of albumin. ABiC was significantly lower (P < .01) in patients with SAH (57.23%) than AC (74.25%) and controls (94.95%, Supplementary Figure 5) . ABiC correlated inversely with ME (r 2 > 0.7, P < .01) in patients with SAH (n ¼ 240; Figure 3D ), suggesting a bilirubin-associated reduction in binding capacity of albumin.
This was confirmed by analyzing the ABiC of in vitro prepared albumin-bilirubin complexes at bilirubin: albumin molar ratio equivalent to SAH, AC, or HC molar ratio. Albumin-bilirubin complex at SAH molar ratio had significantly lower (P < .01) ABiC than AC and HC molar Figure 2 . Plasma level of (A) bilirubin, (B) albumin, (C) bilirubin: albumin molar ratio, and (D) ME of albumin-bilirubin complex in survivors (SAH-S, n ¼ 30) and non-survivors (SAH-NS, n ¼ 60) of SAH in discovery cohort. (E) Correlation of ME with severity and outcome of SAH (n ¼ 90). (F) ROC curve analysis for prediction of 3-month mortality in discovery cohort (n ¼ 90 SAH) and comparison between AUROC for ME, MELD score, and DF for prediction of 3-month mortality in discovery cohort (n ¼ 90 SAH). ratio ( Figure 2E ). The results confirm that overloading of circulatory albumin with bilirubin reduces its binding capacity by hindering the binding sites of albumin in patients with SAH.
Discussion
This study reveals that examination of albuminbilirubin complex in circulation by using CD spectroscopy helps to predict 3-month mortality in patients with SAH. The molar ratio of bilirubin: albumin in circulation is remarkably high in patients with SAH, much more than seen in patients with AC. Alteration in bilirubin: albumin molar ratio influences the interaction of bilirubin with albumin. 5 The binding of bilirubin with albumin forms optically active albumin-bilirubin complex. 8 Because the unbound bilirubin makes no contribution in optical activity, 8 this phenomenon offers advantages for the examination of albumin bilirubin binding in circulation (in vivo). In our study using CD spectroscopy, optical activity (ME) of albumin-bilirubin complex in circulation was measured to describe the interaction between albumin and bilirubin in patients with SAH. Our data clearly demonstrate that in patients with SAH, the interaction of bilirubin with albumin in circulation was remarkably high as compared with AC patients. In patients with SAH, increased albumin-bilirubin interaction influences the formation of optically active albumin-bilirubin complexes by 2 different approaches. First, as the bilirubin: albumin molar ratio rises, more numbers of albumin-bilirubin complexes are formed in circulation. Second, high bilirubin: albumin molar ratio in patients with SAH results in binding of more bilirubin molecules (>1) with 1 albumin molecule. Both of these events collectively result in alteration of CD spectra and increase of ME in patients with SAH. This mode of albumin-bilirubin interaction was previously reported in in vitro settings. 5, 13 This has now been shown in in vivo settings in the present study.
One of the important findings of our study is the ME of the circulatory albumin-bilirubin complex significantly correlates with severity and outcome of SAH. The current study documents an important association of albumin-bilirubin complex with mortality in patients with SAH. Patients with ME cutoff of 1.84 mdeg had significantly higher 3-month mortality in both the derivation and validation cohorts. In fact, ME along with the MELD score was independent predictor of 3-month mortality in these patients after adjusting for other variables. Recently, MELD has been proposed as an indicator of the outcome in patients with SAH. 25 In our study, the HR and concordance index of ME for 3-month mortality in patients with SAH was >10% compared with MELD. This underlines the usefulness of ME for mortality prediction in patients with SAH. In addition, adopting CD spectroscopy for severity assessment in SAH has certain methodological advantages. CD spectroscopy requires a small volume of plasma (500 mL), which could be reused for other biochemical and diagnostic tests. It is a single, simple, and rapid method to assess the severity and outcome in patients with SAH.
Another important finding of our study is that ME inversely correlated with ABiC in patients with SAH. In these patients it is possible that most of the circulatory albumin is saturated with bilirubin, which may hinder the binding sites of other ligands, leading to its functional insufficiency. Thus, we tested the hypothesis if the observed reduction in ABiC in patients with SAH 21 could be a result of the possible hindrance. We observed that with increasing bilirubin concentrations, the binding capacity of albumin decreased, suggesting a temporal association of bilirubin with decrease in binding capacity of albumin.
Many published series have shown the utility of liver support devices as a bridge to liver transplant in patients with SAH. 1, 26, 27 Interestingly, these liver support devices are working on the concept of albumin detoxification. 26, 28 Recent studies demonstrated an increase in ABiC after albumin dialysis, which is because of removal of bilirubin and selective regeneration of patient's albumin. 28 These reports corroborate the theory of bilirubin-related reduction in the binding sites of albumin observed in our study. However, a study by Jalan et al 21 reported no significant differences in albumin functions in patients with alcoholic acute-on-chronic liver failure after MARS therapy. This observation is difficult to explain but could be a result of post-translational modifications of albumin. 15 Our data clearly argue that in patients with SAH, excess binding of bilirubin with albumin contributes to the observed decrease in binding capacity of albumin, although this warrants further investigation. In summary, the present study proposes a very simple, rapid, and highly reproducible diagnostic approach for early prediction of outcome in patients with SAH. The method elaborated in our study also serves as a template for determination of albumin-bilirubin interaction in other forms of liver diseases and albumin-bilirubin related disorders. Moreover, increased interaction between bilirubin and albumin molecules in circulation provides additional information that supports the concept that excessive bilirubin reduces functionality of albumin, and removal of such excessive bilirubin by dialysis may be beneficial in patients with SAH. 
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Supplementary Figure 3 . Comparison of methods for optimization of cutoff value of ME to discriminate SAH nonsurvivors from survivors at 3 months (n ¼ 90 SAH).
Supplementary Figure 4 . KM survival curve analysis in discovery cohort by using the ME cutoff value of 1.84 mdeg (n ¼ 90 SAH).
Supplementary Figure 5 . Measurement of ABiC in total enrolled study population HC (n ¼ 30), AC (n ¼ 60), and SAH (n ¼ 240; discovery cohort 90, validation cohort 150).
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Supplementary Note. Univariate and multivariate Cox regression analysis of ME and different laboratory parameters for determination of potential independency of ME from other parameters in predicting 3-month mortality in SAH patients (n ¼ 240; discovery cohort 90, validation cohort 150). The parameters significant at univariate analysis were subjected to multivariate analysis. CI, confidence interval; HR, hazard ratio.
